Tekla Capital Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $51.6M | Buy |
98,987
+5,282
| +6% | +$2.85M | 2.02% | 15 |
|
|
2023
Q1 | $54M | Hold |
93,705
| – | – | 2.06% | 15 |
|
|
2022
Q4 | $51.6M | Hold |
93,705
| – | – | 1.95% | 16 |
|
|
2022
Q3 | $47.5M | Sell |
93,705
-3,900
| -4% | -$2.18M | 1.95% | 17 |
|
|
2022
Q2 | $53M | Hold |
97,605
| – | – | 2.08% | 14 |
|
|
2022
Q1 | $57.6M | Sell |
97,605
-54,721
| -36% | -$31.4M | 2.02% | 16 |
|
|
2021
Q4 | $102M | Buy |
152,326
+6,210
| +4% | +$3.88M | 3.27% | 5 |
|
|
2021
Q3 | $83.5M | Buy |
146,116
+5,986
| +4% | +$3.29M | 2.69% | 7 |
|
|
2021
Q2 | $70.7M | Buy |
140,130
+26,477
| +23% | +$12.5M | 2.3% | 12 |
|
|
2021
Q1 | $51.9M | Sell |
113,653
-13,900
| -11% | -$6.63M | 1.78% | 17 |
|
|
2020
Q4 | $59.4M | Buy |
127,553
+98,092
| +333% | +$46M | 2.09% | 13 |
|
|
2020
Q3 | $13M | Sell |
29,461
-76,564
| -72% | -$31.6M | 0.49% | 52 |
|
|
2020
Q2 | $38.4M | Sell |
106,025
-6,000
| -5% | -$2.01M | 1.46% | 18 |
|
|
2020
Q1 | $31.8M | Sell |
112,025
-11,383
| -9% | -$3.59M | 1.44% | 16 |
|
|
2019
Q4 | $40.1M | Buy |
123,408
+34,098
| +38% | +$10.3M | 1.52% | 15 |
|
|
2019
Q3 | $26M | Sell |
89,310
-46,888
| -34% | -$13.4M | 1.13% | 22 |
|
|
2019
Q2 | $40M | Sell |
136,198
-6,545
| -5% | -$1.8M | 1.63% | 16 |
|
|
2019
Q1 | $39.1M | Sell |
142,743
-49,152
| -26% | -$12.2M | 1.59% | 16 |
|
|
2018
Q4 | $42.9M | Buy |
191,895
+11,500
| +6% | +$2.7M | 1.84% | 15 |
|
|
2018
Q3 | $44M | Buy |
180,395
+27,700
| +18% | +$6.37M | 1.6% | 17 |
|
|
2018
Q2 | $31.6M | Buy |
152,695
+4,840
| +3% | +$1.03M | 1.2% | 21 |
|
|
2018
Q1 | $30.5M | Buy |
147,855
+9,887
| +7% | +$2.08M | 1.19% | 22 |
|
|
2017
Q4 | $26.2M | Sell |
137,968
-81,104
| -37% | -$15.5M | 1.01% | 26 |
|
|
2017
Q3 | $41.4M | Buy |
219,072
+79,952
| +57% | +$14.5M | 1.48% | 18 |
|
|
2017
Q2 | $24.3M | Sell |
139,120
-88,900
| -39% | -$14.9M | 0.9% | 27 |
|
|
2017
Q1 | $35M | Buy |
228,020
+86,900
| +62% | +$13.3M | 1.36% | 22 |
|
|
2016
Q4 | $19.9M | Buy |
141,120
+54,725
| +63% | +$8.07M | 0.85% | 29 |
|
|
2016
Q3 | $13.7M | Hold |
86,395
| – | – | 0.53% | 43 |
|
|
2016
Q2 | $12.8M | Hold |
86,395
| – | – | 0.52% | 46 |
|
|
2016
Q1 | $12.2M | Hold |
86,395
| – | – | 0.52% | 48 |
|
|
2015
Q4 | $12.3M | Hold |
86,395
| – | – | 0.44% | 48 |
|
|
2015
Q3 | $10.6M | Hold |
86,395
| – | – | 0.38% | 52 |
|
|
2015
Q2 | $11.2M | Sell |
86,395
-55,300
| -39% | -$7.21M | 0.41% | 56 |
|
|
2015
Q1 | $19M | Buy |
141,695
+20,700
| +17% | +$2.67M | 0.75% | 35 |
|
|
2014
Q4 | $15.2M | Sell |
120,995
-145,880
| -55% | -$17.7M | 0.71% | 34 |
|
|
2014
Q3 | $32.5M | Buy |
266,875
+207,215
| +347% | +$25.2M | 1.52% | 18 |
|
|
2014
Q2 | $7.04M | Hold |
59,660
| – | – | 0.65% | 42 |
|
|
2014
Q1 | $7.17M | Buy |
59,660
+49,680
| +498% | +$5.91M | 0.72% | 36 |
|
|
2013
Q4 | $1.11M | Buy |
+9,980
| New | +$992K | 0.12% | 52 |
|
Other funds holding TMO
Tekla Capital Management's TMO Position: Q2 2023 in Review
Tekla Capital Management increased its Thermo Fisher Scientific (TMO) stake by 5.6% in Q2 2023, buying an estimated $2.85M and bringing the position to 98,987 shares worth $51.6M. The position accounts for 2.02% of the portfolio, ranked #15.
Tekla Capital Management first reported a position in TMO in Q4 2013 and has held it in 39 quarters since. The position peaked at $102M in Q4 2021. 2,388 funds tracked by Wall St. Rank hold TMO as of Q2 2023.
- Tekla Capital Management held 98,987 shares of Thermo Fisher Scientific worth $51.6M as of Q2 2023.
- Tekla Capital Management bought 5,282 Thermo Fisher Scientific shares in Q2 2023, an estimated $2.85M.
- Thermo Fisher Scientific made up 2.02% of Tekla Capital Management's portfolio in Q2 2023, its #15 holding.
- Tekla Capital Management first reported a position in Thermo Fisher Scientific in Q4 2013 and has held it in 39 quarters since.
- Tekla Capital Management's Thermo Fisher Scientific position peaked at $102M in Q4 2021.
- 2,388 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2023.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.